Cyclopharm Limited (ASX: CYC) - ETF Exposure

- Current share price for CYC : $0.570

Cyclomedica Limited (CYC) is an ASX-listed company and is held by a number of exchange traded funds (ETFs). It is a health technology company that is a leader in functional lung ventilation imaging. The Company's proprietary product Technegas is a clinical market leader in diagnostic imaging and is available in 66 countries.

CYC General Information ⁺

ASX Code	CYC
Website	http://www.cyclopharm.com.au
Industry/Sector	Health Care Equipment
Market Cap ($M)	71
CYC Share Price	$0.570
Day High	$0.590
Day Low	$0.540
Last Close	$0.570
CYC Share Price Movement	- ( No change )

Prices as at 16:40, 10 Aug 2026

⁺Security prices are delayed by at least 20 minutes and are indicative only.

Already own an Australian ETF? You may already have meaningful exposure to CYC

Cyclopharm Limited (CYC) is held across 1 ETF spanning strategies that include health care equipment exposure . Its weighting in those funds means performance can have an outsized influence - when CYC moves, funds like DACE that hold it can move with it.

For more concentrated exposure, ETFs such as DACE (Dimensional Australian Core Equity (Managed Fund)) allocate about 0% to CYC , while the average exposure across all 1 ETF that hold it is around 0% .

Top ETF holdings

Dimensional Australian Core Equity (Managed Fund) (DACE) ~ 0%

Last updated: ETF data and holdings as at 10 August 2026

Own CYC directly or through an ETF?

How does holding Cyclopharm Limited (CYC) shares directly compare to ETFs that include it?

	CYC Direct	DACE ASX
Holdings	1 company	470 holdings
CYC Weight	100%	0%
Diversification	Single Stock	Broad
Annual Cost	Brokerage only	0.28% p.a.
Approx. Yield	-	2.93%
Star Ratings	-

Yields and costs are approximate. ETF yields reflect the fund's dividend distributions, not CYC's direct yield. Annual cost uses each ETF's MER.

CYC Exposure on $10,000 investment

How a $10,000 investment in Cyclopharm Limited (CYC) one week ago compares with ETFs that hold it.

Security	Investment type	Current price	7-day price movement	Dollar change	Value today
Cyclopharm Limited (CYC)	Direct share	$0.570	2.70%	+$270	$10,270
Dimensional Australian Core Equity (Managed Fund) (DACE)	Equity - Australia Strategy	$19.500	3.83%	+$383	$10,383

Assumes $10,000 invested 7 days ago. Figures are based on price movement only and exclude distributions, fees and brokerage.

Cyclopharm Limited (CYC) ETFs

1 ETF hold Cyclopharm Limited (CYC).

ETF	CYC Weight	MER	Yield
Dimensional Australian Core Equity (Managed Fund) (DACE)	0%	0.28%	2.93%

Cyclopharm Limited (CYC) Upcoming Dividends & Yields

Distribution Type	Dividend	Franking	Ex-dividend date	Payment date	Current Price⁺	Price 7D Avg	Dividend Yield
Result	0.5¢	0%	1 Sep 2023	11 Sep 2023	-	-	-
HFResult	0.5¢	0%	27 Mar 2023	4 Apr 2023	-	-	-
Result	0.5¢	0%	2 Sep 2022	12 Sep 2022	-	-	-

See all dividends from Cyclopharm Limited (CYC) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.

Cyclopharm Limited (CYC) price-sensitive announcements

CYC - New US Lung Imaging Guidelines Name Technegas as Preferred A

Cyclopharm Limited announced that new US lung imaging guidelines have named their product,

Cyclopharm Limited (CYC)
29 Jul 2026 | 8:31 AM

CYC - Immediate 11-Site Technegas Rollout at University Hospitals

Cyclopharm Limited has announced a significant agreement with University Hospitals in Clev

Cyclopharm Limited (CYC)
15 Jul 2026 | 8:29 AM

CYC - CYC First-Half 2026 Update

Cyclopharm Limited reported a record revenue growth of 11% for the first half of FY26, pri

Cyclopharm Limited (CYC)
2 Jul 2026 | 10:11 AM

CYC - USA Technegas Expansion Update

Cyclopharm Limited has provided an update on its expansion in the United States, highlight

Cyclopharm Limited (CYC)
31 Mar 2026 | 8:42 AM

Cyclopharm Limited (CYC) Recent ASX Announcements

Company	Sector	Market Cap ($m)	Headline	Release date/time⁺	Price at release⁺	Current price⁺	Gain/Loss
Cyclopharm Limited (CYC) ORDINARY FULLY PAID	Health Care	$72	New US Lung Imaging Guidelines Name Technegas as Preferred A	29 Jul 2026 8:31AM	$0.520	$0.570	risen by 9.62%
Cyclopharm Limited (CYC) ORDINARY FULLY PAID	Health Care	$72	ausbiz TV Presentation	28 Jul 2026 8:50AM	$0.540	$0.570	risen by 5.56%
Cyclopharm Limited (CYC) ORDINARY FULLY PAID	Health Care	$72	Immediate 11-Site Technegas Rollout at University Hospitals	15 Jul 2026 8:29AM	$0.485	$0.570	risen by 17.53%
Cyclopharm Limited (CYC) ORDINARY FULLY PAID	Health Care	$72	Notification of cessation of securities - CYC	6 Jul 2026 3:05PM	$0.515	$0.570	risen by 10.68%
Cyclopharm Limited (CYC) ORDINARY FULLY PAID	Health Care	$72	CYC First-Half 2026 Update	2 Jul 2026 10:11AM	$0.510	$0.570	risen by 11.76%
Cyclopharm Limited (CYC) ORDINARY FULLY PAID	Health Care	$72	Change in substantial holding	25 Jun 2026 5:19PM	$0.500	$0.570	risen by 14%

CYC Financial Summary

Year to Dec	NPAT	EPS	EPS chg (%)	DPS	Yield (%)	Franking (%)
2025A	-$13.88	-$12.60	-1.80%	0.00	0.00%	0.0%
2024A	-$13.21	-$12.80	28.20%	0.00	0.00%	0.0%
2023A	-$9.28	-$10.00	39.60%	0.50	0.30%	0.0%

CYC Peer Comparison

Company	Mkt Cap	EPS Growth (%)			P/E (%)			Dividend Yield (%)
Company	Mkt Cap	2023 A	2024 A	2025 A	2023 A	2024 A	2025 A	2023 A	2024 A	2025 A
Cochlear Limited (COH)	$8,166M	0.0171	-0.1894	0.0615	20.8646	25.7401	24.2480	3.44%	2.78%	2.88%
Cyclopharm Limited (CYC)	$69M	-0.0179	0.0000	0.0000	0.0000	0.0000	0.0000	0.00%	0.00%	0.00%
Fisher & Paykel Healthcare Corporation Limited (FPH)	$20,520M	0.1388	0.1477	0.1883	52.8353	46.0343	38.7404	1.24%	1.34%	1.52%
ResMed Inc. (RMD)	$17,072M	0.3087	9.7744	0.0595	198.5557	18.4284	17.3937	1.16%	1.22%	1.28%

CYC Market Comparison

	Earnings	P/E Ratio	P/B Ratio	P/E Growth
Company	0.00	0.00	2.34	0.00
Market	0.31	13.10	1.15	0.69
Sector	0.73	19.20	1.65	1.92

CYC Directors

Name	Position	Start Date
Mr James S McBrayer	Chief Executive Officer, Managing Director, Company Secretary	3 Jun 2008
Mr Douglas Ernest Charles Cubbin	Non-Executive Chairman, Non-Executive Director	4 May 2026
Ms Dianne Margaret Angus	Non-Executive Director	10 Aug 2021
Dr Gregory George King	Non-Executive Director	27 Sep 2022

Cyclopharm Limited (CYC) Changes in Directors' Interest & Trades

Date of change	Director	Buy/Sell	Security Type	Qty	Trade Price	Value
12 Mar 2026	HEANEY, David	Buy	Direct Shares	21,052	$0.950	$19,999.400
12 Mar 2026	BARROW, Kevin	Buy	Indirect Shares	5,263	$0.950	$4,999.850
12 Mar 2026	WIGGLESWORTH, John	Buy	Direct Shares	21,052	$0.950	$19,999.400

See all changes in directors' interest & trades for Cyclopharm Limited (CYC) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.

CYC Management

Name	Position
Jason Smith	Chief Financial Officer
Mathew Farag	Chief Operating Officer

CYC Substantial Shareholders

Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in Cyclopharm Limited (CYC). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.

Holding	Name
13,211,332 (12.20%)	Anglo Australian Christtan and Charitable Fund
12,002,783 (11.31%)	Regal Funds Management Pty Ltd
11,444,962 (10.57%)	Barings Acceptance Limited
9,867,556 (8.88%)	National Nominees Ltd
9,188,008 (8.49%)	Chemical Overseas Limited
6,644,758 (6.14%)	CVC Limited
7,067,962 (5.86%)	Investors Mutual Limited

CYC Calendar of Events

Date	Event
26 March 2027	Report (Annual)
24 February 2027	Report (Prelim)
01 September 2026	Report (Interim)
26 August 2026	Report (Interim)

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.

What our members say about us